Varian Medical Systems — 2017 ASTRO Investor Relations Meeting
55 slides from Varian Medical Systems's conference presentation, Sep 26, 2017

Slide 1: 2017 ASTRO Investor Relations Meeting: Transforming Cancer Care
Varian confidential/proprietary: disclosed for immediate recipient only 2017 ASTRO Investor Relations Meeting Transforming Cancer Care

Slide 2: Agenda
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Agenda 2 Treatment Delivery Technologies, HyperArc TM & Adaptive Therapy Ed Vertatschitsch Vice President, Global Portfolio Solutions Treatment Planning Systems Eric Lindquist Vice President, Clinical Solut

Slide 3: Forward Looking Statements
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 3 THIS PRESENTATION IS INTENDED EXCLUSIVELY FOR INVESTORS. IT IS NOT INTENDED FOR USE IN SALES OR MARKETING. FORWARD LOOKING STATEMENTS Except for historical information, this presentation contains forward-

Slide 4: Overview
Varian confidential/proprietary: disclosed for immediate recipient only Varian Overview Dow R. Wilson President and Chief Executive Officer

Slide 5: Varian today – a snapshot
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Varian today – a snapshot 5 * Varian FY 16, excluding Imaging Components. ** YTD thru Fiscal 3 rd quarter 2017 Gross Orders, excluding North America A focused cancer company Global Leader in radiation thera

Slide 6: Long-term growth and value creation strategy
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Medical oncology Precision medicine Diagnostic imaging Radiation oncology Interventional oncology Surgical oncology Long - term growth and value creation strategy 6 Global Leader in Radiation Therapy #1 Glo

Slide 7: Growth priorities and strategic enablers
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Growth priorities and strategic enablers 7 We are here Global Leader in Radiation Therapy Integrated, Human - Centered Cancer Treatment Strengthen Leadership in Radiation Therapy Extend Global Footprint Exp

Slide 8: In summary
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 8 In summary • Global market leader today with the strongest portfolio • Strengthening our leadership in radiation therapy • Growth - focused in both developed and developing markets • Financially disciplin

Slide 9: Proton Therapy
Varian confidential/proprietary: disclosed for immediate recipient only Proton Therapy Moataz Karmalawy VP & General Manager Worldwide Particle Therapy

Slide 10: Proton therapy plays a critical role in strengthening our leadership
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Proton therapy plays a critical role in strengthening our leadership Key luminaries adding proton therapy Protons expand to new disease sites Innovation leader IMPT and compact systems Melanoma of the eye B

Slide 11: True integration
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY True integration 11 Simplification, automation, human - centered design ARIA ® Oncology Information System 360 Oncology ™ Care Management Platform Velocity ™ Oncology Image Informatics Eclipse ™ Treatment P

Slide 12: ProBeam installations
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY PAUL SCHERRER INSTITUTE (PSI) 1 Rotational Gantry MARYLAND PROTON TREATMENT CENTER 4 Rotational Gantries and 1 Fixed Beam Room HEFEI ION MEDICAL CENTER 3 Rotational Gantries, 1 Fixed Beam, and 1 Research Ro

Slide 13: Extending global footprint: ProBeam approvals
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Extending global footprint: ProBeam ® approvals ProBeam ® now has clearance in the US, Europe and Japan FDA Clearance in US CE Mark in Europe Shonin Clearance in Japan 11

Slide 14: Large growth opportunity in China
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 14 Large growth opportunity in China • 2 proton centers in operation • 10 proton centers in progress • 15 - 20 proton purchase contracts in next 10 years • Varian with first government - funded project in H

Slide 15: ProBeam: Integrated, human-centered cancer treatment
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 15 ProBeam I ntegrated , human - centered cancer treatment

Slide 16: Oncology Systems
Varian confidential/proprietary: disclosed for immediate recipient only Oncology Systems Kolleen T. Kennedy President, Oncology Systems Treatment Delivery Technologies Adaptive Therapy Ed Vertatschitsch Vice President, Global Portfolio Solutions Treatment Planning Systems Eric Lindquist Vice Preside

Slide 17: Oncology Systems
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Oncology Systems 17

Slide 18: ASTRO highlights
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY ASTRO highlights 18 Varian Presence • First Halcyon patient treated at Penn Medicine; UCSD also treating • First HyperArc TM treatment in Negrar , Italy • Strong attendance and participation ; 1,054 custome

Slide 19: Varian market leadership
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Varian market leadership 19 Leading provider of integrated, human - centered cancer treatment solutions Halcyon growth enabler in single L inac centers, small vaults IMV t op scores in all key categories Po

Slide 20: The Varian ecosystem promise delivered
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY The Varian ecosystem promise delivered 20 Intelligent Treatment Delivery • Halcyon platform launch • HyperArc SRS • iCBCT soft tissue visualization Knowledge - Based Oncology • Eclipse • RapidPlan • Multi -

Slide 21: Oncology growth drivers
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Oncology growth drivers • Global Demographics • Winning Innovation Strategy • Emerging Markets Opportunity • Services Business Expansion • Software Momentum • Aging Installed Base 21 Long - term goal 6M pat

Slide 22: Treatment Delivery Systems
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Treatment Delivery Systems 22

Slide 23: Halcyon for value-based healthcare
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Halcyon for value - based healthcare 23 Accelerate installation and clinical go - live Reduce footprint and cost of ownership Treat more patients per day with ease High - quality image - guided IMRT treatme

Slide 24: Accessing markets worldwide: regulatory progress
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Accessing markets worldwide: regulatory progress 24 Cleared In - process No clearance required • Parallel filings in major markets • Clearance in 113 countries • Filings under government review: China, Japa

Slide 25: First-in-country orders
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY First - in - country orders • Australia • Belgium • India • Morocco 25 • Romania • Russia • Turkey • UK

Slide 26: Operational readiness at a global scale
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Operational readiness at a global scale 26 Manufacturing Sites Education Centers Parts Depots FOR INVESTOR USE ONLY

Slide 27: Halcyon strengthens radiotherapy leadership
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Strengthens radiotherapy leadership • Leverage core linac competency • Enable key intellectual property • Develop critical supply chain 27 • Delivers outstanding clinical quality • Enhances patient comfort

Slide 28: Halcyon summary
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 28 FOR INVESTOR USE ONLY Extends global access to world - class radiotherapy Delivers total value of ownership for hospitals Establishes a next - gen platform for future innovation Halcyon summary

Slide 29: Adaptive Therapy
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Adaptive Therapy 29

Slide 30: Patients and tumors change over time
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 30 Patients and tumors change over time • Tumors shrink and change shape as they respond to therapy • Patient physiology may change due to weight loss and medication • Treatment plans should adapt Adaptive

Slide 31: Future of RT requires combined modalities
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Future of RT requires combined modalities 31 Only Varian Multi - modality imaging at point of care Single - modality image - guidance Other approaches Lower left image courtesy of Siemens Healthineers . CT

Slide 32: Therapeutic accuracy is vital
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Therapeutic accuracy is vital Fast and accurate adaptive workflow is critical for the patient comfort, stability, and clinic efficiency Treatment Fidelity High - definition treatment enables delivered dose

Slide 33: Adaptive therapy strategy
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 33 Adaptive therapy strategy Strengthening Varian’s leadership in radiation oncology through: • Multimodality imaging ; Available for every patient ; Most informed adaptive decisions • Iterative CBCT for ac

Slide 34: HyperArc
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY HyperArc TM 34

Slide 35: Global need for SRS solutions
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Global need for SRS solutions 32 1 DeSantis CE, Cancer treatment and survivorship statistics, 2014 CA. Metastatic brain cancer ~15M patients over 5 years of cancer patients will develop brain metastases 1 4

Slide 36: HyperArc high-definition radiotherapy
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY HyperArc ™ high - definition radiotherapy 36 Establishing new benchmarks for radiosurgery Treatment quality • Algorithms unlock TrueBeam /Edge system capabilities • Maximize healthy tissue sparing Unmatched

Slide 37: HyperArc high-definition radiotherapy: $300M opportunity
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 37 HyperArc ™ high - definition radiotherapy • TrueBeam and Eclipse upgrade opportunity • High product and service margins • Potential to accelerate older system replacements Benchmark radiosurgery scalable

Slide 38: Treatment Planning Systems
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Treatment Planning Systems 38

Slide 39: Treatment planning
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Treatment planning • For the fourth year in a row, Eclipse named category leader by KLAS • Over 3,900 Eclipse customers worldwide • 900+ RapidPlan licenses growing double digits 36

Slide 40: Treatment planning workflow
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Treatment planning workflow 40 Contouring Plan Optimization Dose Calculation Eclipse TM Benefits • Accuracy • Efficiency • Flexibility • Automation • Interactivity • Speed

Slide 41: RapidPlan: Transforming efficiency
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Contouring Plan Optimization Dose Calculation Trade - Off Analysis RapidPlan 41 Transforming efficiency Knowledge Guidance RapidPlan

Slide 42: RapidPlan benefits
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Benefits Quality Increased Consistency Efficiency RapidPlan 42 Transforming efficiency

Slide 43: Multi-Criteria Optimization
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Multi - Criteria Optimization 43 Transforming efficiency Contouring Plan Optimization Dose Calculation Trade - Off Analysis Plan Fine Tuning Multi - Criteria Optimization

Slide 44: RapidPlan + Multi-Criteria Optimization
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY RapidPlan + Multi - Critera Optimization 44 Efficient and patient centric RapidPlan MCO

Slide 45: Multi-Criteria Optimization benefits
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Multi - Criteria Optimization For Varian • Strengthens leadership position • Drives incremental RapidPlan adoption • Extends global footprint 45 For Clinicians • Allows for fine - tuning and customizing eac

Slide 46: Driving customer productivity
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Driving customer productivity 46 Increased GPU speed* Contouring Plan Optimization Dose Calculation Trade - Off Analysis GPU Speed GPU Speed GPU CPU 25x improvement 5x improvement 5x improvement Lung Total

Slide 47: Eclipse treatment planning
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 47 Eclipse treatment planning • Solid core user base of over 3,900 customers worldwide • High - value upgrades to customers • HyperArc and RapidPlan are unique value creators • MCO and GPU elevate planning

Slide 48: Oncology Continuum Solutions
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY Oncology Continuum Solutions 48

Slide 49: ARIA: market-leading oncology information system
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY ARIA: market - leading oncology information system • Extending global footprint with localization • Strengthening leadership with cybersecurity • Timely compliance with US regulations • Rapid expansion of i

Slide 50: InSightive: real-time insights, better informed decisions
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY • An intuitive analytics solution built specifically for the oncology department • Simple, interactive exploration of oncology data to uncover patterns and trends • Helps improve care, operational performan

Slide 51: Velocity software
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY • Organizes unstructured and disparate patient image data into rich patient history • Uses images to provide clinical insights for tumor response and treatment planning • Vendor - neutral platform for the m

Slide 52: Streamlining Multi-Disciplinary Tumor Boards
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 52 360 Oncology Enabling simpler, smarter cancer care Streamlining Multi - Disciplinary Tumor Boards 1 1 Financial analysis based on British Journal of Cancer (2013) 109, 2295 – 2300 | doi : 10.1038/bjc.201

Slide 53: Building the operating system for cancer care
Varian confidential/proprietary: disclosed for immediate recipient only FOR INVESTOR USE ONLY 53 360 Oncology Building the operating system for cancer care • Early entry into the $1B+ market for oncology care coordination and clinical decision support • Focus on serving critical unmet needs in oncol

Slide 54: Closing Remarks
Varian confidential/proprietary: disclosed for immediate recipient only Closing Remarks Dow R. Wilson President and Chief Executive Officer

Slide 55: FOR INVESTOR USE ONLY
FOR INVESTOR USE ONLY 55
Source: SEC EDGAR · 8-K filed Sep 26, 2017
More decks from Varian Medical Systems Inc
Q1 FY2021 Earnings Presentation29 slides · Jan 26, 2021
Q4 FY2020 Earnings Presentation30 slides · Oct 27, 2020
Merger or Acquisition (August 2020)33 slides · Aug 4, 2020
Merger or Acquisition (August 2020)18 slides · Aug 3, 2020
Q3 FY2020 Earnings Presentation36 slides · Aug 3, 2020
Q2 FY2020 Earnings Presentation36 slides · May 4, 2020